

All breast cancer patients in the South Sweden healthcare region diagnosed between Sept. 1 2010 and Mar. 31 2015 and operated for invasive primary* breast cancer (n=5892 patients)

Not enrolled (n=791)

Enrolled SCAN-B patients (n=5101 patients, 87%)

No tumor tissue for study (n=1205) or tumor tissue obtained after neoadjuvant therapy or previous biopsy (n=49)

Enrolled patients with tumor biopsy sample for analysis (n=3847 patients, 75%)

Insufficient or poor quality RNA and RNA-seq not performed or failed (n=464); RNA-seq data failed QC (n=110)

Validation cohort with quality controlled RNA-seq data (n=3273 patients, 85%)